| Name | receptor tyrosine kinase |
|---|---|
| Synonyms | CAK; Protein tyrosine kinase; NEP; Receptor tyrosine kinase; CD167; CD167a antigen; Cell adhesion kinase; DDR… |
| Name | SMA |
|---|---|
| CAS | sodium 2-chloroacetate |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 19997799 | Ohta M, Kawabata T, Yamamoto M, Tanaka T, Kikuchi H, Hiramatsu Y, Kamiya K, Baba M, Konno H: TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model. Surg Today. 2009;39(12):1046-53. Epub 2009 Dec 8. |
2(0,0,0,2) | Details |
| 18674914 | Reiner DJ, Ailion M, Thomas JH, Meyer BJ: C. elegans anaplastic lymphoma kinase ortholog SCD-2 controls dauer formation by modulating TGF-beta signaling. Curr Biol. 2008 Aug 5;18(15):1101-9. We map this defect in dauer response to a mutation in the scd-2 gene, which, we show, encodes the nematode anaplastic lymphoma kinase (ALK) homolog, a proto-oncogene receptor tyrosine kinase. scd-2 acts in a genetic pathway shown here to include the HEN-1 ligand, the RTK adaptor SOC-1, and the MAP kinase SMA-5. |
1(0,0,0,1) | Details |
| 17935226 | Tugues S, Fernandez-Varo G, Munoz-Luque J, Ros J, Arroyo V, Rodes J, Friedman SL, Carmeliet P, Jimenez W, Morales-Ruiz M: Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology. 2007 Dec;46(6):1919-26. This study thus evaluates the therapeutic use of the multitargeted receptor tyrosine kinase inhibitor Sunitinib (SU11248). |
1(0,0,0,1) | Details |
| 20177740 | Deng B, Yang X, Liu J, He F, Zhu Z, Zhang C: Focal adhesion kinase mediates TGF-beta1-induced renal tubular epithelial-to-mesenchymal transition in vitro. Mol Cell Biochem. 2010 Feb 23. Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase which participates in many important cellular processes such as cell adhesion and migration. |
1(0,0,0,1) | Details |
| 18435859 | Piechocki MP: A stable explant culture of HER2/neu invasive carcinoma supported by alpha-Smooth Muscle Actin expressing stromal cells to evaluate therapeutic agents. BMC Cancer. 2008 Apr 24;8:119. The stability of this model and the ability to antigenically label the tumor and stromal fractions allowed us to determine the specificity of Iressa, a receptor tyrosine kinase inhibitor, for targeting the tumor cell population. |
1(0,0,0,1) | Details |